ASND

Ascendis Pharma AS

270.56 USD

Last updated Sep 4, 19:37 UTC

Yesterday HIGH

$272.44

Yesterday LOW

$265.87

52w HIGH

$282.15

52w LOW

$186.05

EPS

1.05

PE

257.68

Next Earnings

Nov 11, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Ascendis Pharma AS stock is up 10.79% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 11 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

27 Aug 14:37	15 Jan, 2027	270.00	CALL	20	62
27 Aug 16:02	18 Dec, 2026	280.00	CALL	200	20
27 Aug 16:03	18 Dec, 2026	250.00	PUT	200	1
28 Aug 19:25	16 Oct, 2026	230.00	PUT	158	1
31 Aug 13:37	16 Oct, 2026	330.00	PUT	5	0
31 Aug 13:38	18 Dec, 2026	330.00	CALL	132	134
31 Aug 13:54	16 Oct, 2026	290.00	PUT	12	0
31 Aug 18:48	18 Sep, 2026	280.00	CALL	100	32
31 Aug 18:49	18 Sep, 2026	280.00	CALL	99	32
01 Sep 13:51	18 Sep, 2026	180.00	CALL	5	9

Advanced Data Unlock

Benzinga Newsdesk

Fri Aug 14, 2026

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
Benzinga Newsdesk

Fri Aug 14, 2026

Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
Benzinga Insights

Thu Aug 13, 2026

Full Transcript: Ascendis Pharma Q2 2026 Earnings Call

Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
Benzinga Newsdesk

Thu Aug 13, 2026

Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of $(0.93) per share from
Benzinga Insights

Tue Aug 11, 2026

Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market capitalization of
Benzinga Newsdesk

Thu Aug 6, 2026

Ascendis Pharma Says Week 78 COACH Data Show TransCon CNP Plus TransCon hGH Combination Tripled Height Z-Score Efficacy vs. Monotherapy In Achondroplasia; Reports Over 170 YUVIWEL US Patient Enrollments
Benzinga Newsdesk

Thu Jul 23, 2026

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.
Benzinga Newsdesk

Tue Jul 7, 2026

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.
Benzinga Newsdesk

Fri Jun 26, 2026

Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell Midcap

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell
Benzinga Newsdesk

Thu Jun 25, 2026

Ascendis Pharma shares are trading higher. Strength may be due to increased trader interest in response to rumored acquisition commentary.

Morgan Stanley

Tue Sep 1, 18:10

buy

confirm
Wedbush

Tue Sep 1, 14:18

buy

confirm
Bank of America

Mon Aug 31, 19:44

buy

confirm
Jefferies

Mon Aug 31, 19:30

buy

confirm
Stifel

Mon Aug 31, 19:14

buy

confirm
HC Wainwright & Co.

Mon Aug 31, 17:53

buy

confirm
HC Wainwright & Co.

Mon Aug 31, 12:30

buy

confirm
HC Wainwright & Co.

Thu Aug 27, 14:16

buy

initial
BMO Capital

Wed Aug 19, 12:06

buy

initial
TD Cowen

Fri Aug 14, 17:59

buy

confirm
RBC Capital

Fri Aug 14, 17:23

buy

confirm
Barclays

Fri Aug 14, 16:18

buy

confirm